Sublingual immunotherapy in dust mite allergy

Trial Profile

Sublingual immunotherapy in dust mite allergy

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Perennial allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Mar 2009 Efficacy results have been published in the proceedings of the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 17 Mar 2009 Safety and tolerability results have been published in the proceedings of the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 21 Nov 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top